REALATED ARTICLES

Click on a word or phrase in our Tag Cloud and see all related articles listed below.

 

Current tag:

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

Prof. Andreas BuschJanuary 2011. An unmasked account of decisions about investing into cancer stem cell research and the fate of regenerative medicine projects in Japan. Dr Busch summarises results and evaluates technology platforms like novel antibodies and wnt mechanisms. He voices his expectations from current key drug development partnerships, in particular with Oncomed and Micromet. Will these include companion diagnostics? To what extent does Bayer retain respective intellectual property rights? A comment on personalised medicine and cancer stem cells research pursued by Merck KGaA and others. What are prospects for classic oncology drugs?

 

 

 

Related Articles

Horizon Discovery: Mitigating risks and developing the U.S. business

Tasks ahead for Eric Rhodes, the new CTO

Roche Ethiopia: Build-up of an emerging market

Systems Biology: In search of good questions

Prof Walter Kolch on the approach taken by Systems Biology Ireland


B2Bioworld Stem Cell Insights Collection 2010:

Issues and Evaluation from Pharma Leaders

 

Dr Patrick Vallance, GSK:

Stem Cell Research Now and in the Future

 

No Mercy with Violators of Corporate Compliance

Dr Rüdiger Scheitza, Member of the Board Bayer CropScience, and Labour Director

 



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

3 pages, exclusive

P.Vallance, GSK: Stem Cell Research Now and in the Future

(C) Dr Patrick Vallance 2008November 2009. “Stem cells provide novel opportunities that didn't previously exist” says Dr Patrick Vallance, Head of GlaxoSmithKline’s Drug Discovery in an interview with B2Bioworld. He describes his company’s approach. What is the role of cancer stem cells? What about novel drugs like lapatinib or trastuzumab? Which collaborations are desirable? The report includes stem cell issues yet unattended by pharma.



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

exclusive interview 3 pages

Clear away complete confusion of terms - The case of stem cell research

Dr Bernhard Kirschbaum (C) Wolf G Kroner 2009 February 2009. While many ethical questions surrounding the use of stem cells have been satisfactorily answered, a number of unresolved methodological and technical issues hamper applications in the pharmacceutical industry. Where are the stumbling blocks of today? What is Merck’s and Merck Serono’s approach, and with what prospects?

 

 

Related Articles

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

The Myriad Way

Peter D Meldrum, CEO of the genetics company on battles about patents, cancer chips, and competitors in commercial academia

Stem Cells - Failings and Deliveries

Towards Pharma Standards for Assays: Drug Testing with Embryonic Stem Cells

 

 

or access the complete Stem Cell Insights Collection



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

exclusive interview, 2 pages

Top 10 Tags

All Tags (2094)